NCT02373098 - Fingolimod Effect on Cytokine and Chemokine Levels | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 18, 2017

Study Completion Date

January 18, 2017

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Fingolimod 0.5 mg

66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.

Trial Locations (3)

34093

Novartis Investigative Site, Istanbul

34394

Novartis Investigative Site, Mecidiyeköy

34668

Novartis Investigative Site, Üsküdar